Metropolitan Life Insurance CO Lineage Cell Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$0.86 - $1.48 $1,432 - $2,465	1,666 New	1,666 $2,000
Q2 2023 Aug 10, 2023	BUY	$1.26 - $1.53 $8,977 - $10,901	7,125 New	7,125 $10,000
Q1 2022 May 12, 2022	SELL	$1.21 - $2.48 $21,262 - $43,578	-17,572 Closed	0 $0
Q4 2021 Jun 21, 2023	BUY	$1.84 - $2.68 $32,332 - $47,092	17,572 New	17,572 $43,000
Q4 2021 Mar 30, 2023	SELL	$1.84 - $2.68 $2,771 - $4,036	-1,506 Reduced 7.89%	17,572 $43,000
Q4 2021 Feb 15, 2022	SELL	$1.84 - $2.68 $2,771 - $4,036	-1,506 Reduced 7.89%	17,572 $43,000
Q3 2021 Jun 21, 2023	BUY	$2.26 - $2.86 $43,116 - $54,563	19,078 New	19,078 $48,000
Q3 2021 Mar 30, 2023	SELL	$2.26 - $2.86 $44,366 - $56,144	-19,631 Reduced 50.71%	19,078 $48,000
Q3 2021 Nov 15, 2021	SELL	$2.26 - $2.86 $44,366 - $56,144	-19,631 Reduced 50.71%	19,078 $48,000
Q2 2021 Jun 21, 2023	BUY	$2.17 - $3.0 $83,998 - $116,127	38,709 New	38,709 $110,000
Q2 2021 Mar 30, 2023	BUY	$2.17 - $3.0 $83,998 - $116,127	38,709 New	38,709 $110,000
Q2 2021 Aug 16, 2021	BUY	$2.17 - $3.0 $83,998 - $116,127	38,709 New	38,709 $110,000

120

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $91.7M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.